Pfizer
PFE
2,996 hedge funds and large institutions have $100B invested in Pfizer in 2024 Q4 according to their latest regulatory filings, with 381 funds opening new positions, 934 increasing their positions, 1,466 reducing their positions, and 246 closing their positions.
55% more first-time investments, than exits
New positions opened: 381 | Existing positions closed: 246
3% more funds holding
Funds holding: 2,910 → 2,996 (+86)
0% more funds holding in top 10
Funds holding in top 10: 42 → 42 (0)
0.21% less ownership
Funds ownership: 66.47% → 66.25% (-0.21%)
8% less capital invested
Capital invested by funds: $109B → $100B (-$8.72B)
15% less call options, than puts
Call options by funds: $3.28B | Put options by funds: $3.87B
36% less repeat investments, than reductions
Existing positions increased: 934 | Existing positions reduced: 1,466
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
+$687M |
| 2 |
BlackRock
New York
|
+$427M |
| 3 |
SV
Starboard Value
New York
|
+$417M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$185M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$147M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$644M |
| 2 |
Millennium Management
New York
|
-$337M |
| 3 |
Amundi
Paris,
France
|
-$293M |
| 4 |
JP Morgan Chase
New York
|
-$285M |
| 5 |
Barclays
London,
United Kingdom
|
-$277M |
PFE Hedge Fund Activity: Q4 2024 in Review
2,996 of the 7,594 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2024, worth a combined $100B — down 8% from $109B a quarter earlier.
Buyers outnumbered sellers: 381 funds opened new PFE positions and 246 closed out — a net gain of 135 holders — while 934 added to existing stakes and 1,466 trimmed.
The largest buyer was Charles Schwab, adding an estimated $687M. The largest seller was Wellington Management Group, cutting an estimated $644M.
- 2,996 institutional investors held Pfizer (PFE) as of Q4 2024, up from 2,910 in Q3 2024.
- Funds reported $100B of Pfizer stock for Q4 2024, down 8% quarter-over-quarter.
- 381 funds opened new Pfizer positions in Q4 2024 and 246 closed out, a net change of +135 holders.
- The largest Pfizer buyer in Q4 2024 was Charles Schwab, an estimated $687M added.
- The largest Pfizer seller in Q4 2024 was Wellington Management Group, an estimated $644M sold.
Based on aggregated 13F filings for Q4 2024.